The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate <b>2ab> is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.